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LEADING ARTICLEAn Endovascular Strategy for Suspected Ruptured Abdominal Aortic
Aneurysm Brings Earlier Home Discharge but Not Early Survival or Cost
Beneﬁts
IMPROVE Trial Investigators *,1Many patients with suspected ruptured abdominal aortic
aneurysm (AAA) are likely to present at a hospital which
may not be able to offer either emergency repair or
emergency repair by both endovascular and open emer-
gency repair. Within the past year, two small trials of hae-
modynamically stable patients with aortic anatomy suitable
for conventional endovascular aneurysm repair (EVAR) have
shown that, in specialist centres, operative mortality is
similar after either open or endovascular repair (20e
25%).1,2 However, in practice the aortic anatomy is un-
known at the time of early clinical suspicion of ruptured
AAA and shock may develop rapidly, so where should these
patients be treated? This was the question underpinning
the IMPROVE trial. Is the operative mortality lower with an
endovascular strategy versus open repair, and consequently
should the patient be directed to a hospital offering a 24/7
endovascular service?
The IMPROVE trial randomized 613 patients with a clin-
ical diagnosis of ruptured AAA to either an endovascular
strategy, with an urgent computed tomography (CT) scan
followed by EVAR or open repair for adverse aortic anat-
omy, or to an open repair strategy, where CT scan was
optional. This was a pragmatic, “real-world” trial, with a
high proportion of known hospital presentations of
ruptured aneurysm being randomized. The last patient was
randomized in July 2013 and the primary outcome from this
trial (30-day mortality) has been presented recently.3
Overall there was no difference in 30-day mortality, 35%
in the endovascular strategy group versus 37% in the open
repair group. These results included those patients who
died before surgery (6%), patients with suitable anatomy for
EVAR who crossed over to open repair because either fa-
cilities or personnel for EVAR were not immediately avail-
able or the patient deteriorated rapidly and it was quicker
to start open repair (5%), those randomized to open repair
but crossed over to EVAR because of their frailty or clinical
decision concerning their suitability for general anaesthesia
(6%), as well as those with symptomatic aneurysms (4%) or
other ﬁnal diagnoses (9%). In the AJAX trial, the mean time
to arrival in an operating suite for endovascular repair was
over 70 minutes, almost 30 minutes longer than the time* Corresponding author. Vascular Surgery Research Group, Imperial College,
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IMPROVE trial, the time for patients with rupture to reach
the operating suite was much shorter, 37 and 47 minutes
for the open and endovascular groups respectively. Never-
theless, the longer time needed for patients to reach
endovascular repair could provide a potential disadvantage.
Following this initial delay, patients surviving repair left
theatre alive at similar times after randomization in each
group, since the median length of the procedure was 180
minutes for the endovascular strategy and 199 minutes for
the open repair group.
For the patients with aneurysms in the endovascular
strategy group, 64% were considered to be anatomically
suitable for conventional EVAR and, among those treated
with EVAR, the operative mortality was 25%, very similar to
the results for EVAR in the AJAX and ECAR trials. In contrast,
the operative mortality following open repair in this group
was 38% compared with the 37% operative mortality in the
open repair group. The results for open repair appear worse
than those reported from the AJAX and ECAR trials, but
IMPROVE included patients in shock and those with adverse
aortic anatomy.
The IMPROVE trial also reported 30-day costs, which
showed that the endovascular group had greatly reduced
stay in intensive care, which offset the extra cost of endo-
vascular devices. On balance, costs after 30 days were non-
signiﬁcantly lower in the endovascular strategy group.
With a trial of this size, limited subgroup analysis was
possible. Surprisingly, for the 133 women survival was
better with an endovascular strategy, odds ratio 0.44
(95% CI 0.22e0.91). Hardman index was a good prognostic
indicator for both endovascular and open repairs and
additional analysis of the ruptured aneurysm cohort
showed the direct linear relationship between lowest sys-
tolic blood pressure and operative mortality (51% for those
with pressures < 70 mmHg), which questions the thresh-
olds recommended for hypotensive haemostasis.4 Patients
transferred from hospitals not offering emergency repair
had similar risk proﬁles and outcomes as patients present-
ing directly to the trial hospitals.4 Patients who received
endovascular repair under local anaesthesia had a lower
mortality (13%) than those who underwent the procedure
under general anaesthesia (34%), which translated to a
fourfold beneﬁt for local anaesthesia after adjustment for
prespeciﬁed confounders, odds ratio 0.25 (95% CI 0.10e
0.70). Patients in the endovascular strategy group were
discharged from hospital faster and a much greater number
334 IMPROVE Trial Investigators(94%) were discharged directly to home rather than step-
down care (vs. just 77% in the open repair group). This
latter outcome, number of patients being discharged to
home, was the primary outcome measure favoured by pa-
tients and their families when they were consulted about
the trial design. Neither this outcome nor in-hospital mor-
tality emerged as the favoured primary outcome after the
proposal for the trial emerged from peer review. Never-
theless, based on the IMPROVE results to date both pa-
tients and their families are likely to favour endovascular
repair when this is feasible.
So the IMPROVE trial has again shown that for patients
with good aortic anatomy and relative haemodynamic sta-
bility, the operative mortality for EVAR is only 25%, but this
only represents about 60% of the cohort presenting for
emergency aneurysm repair. In those who need open repair
(either for anatomical reasons or extreme urgency), mor-
tality is much higher (38%). Given the observations that
survival with discharge directly to home is higher and costs
non-signiﬁcantly lower in the endovascular group, it may be
that patients with ruptured abdominal aortic aneurysms
should be treated in centres that can offer both endovas-
cular and open aortic surgery at all times. However, it re-
mains crucial to identify both which patients beneﬁt from
endovascular repair and whether the endovascular strategy
is cost-effective after longer patient follow up before ﬁnal
decisions are made about altering the provision of hospital
services for ruptured AAA.
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